Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Stryker Corporation    SYK

STRYKER CORPORATION (SYK)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles

Stryker : Says It Isn't in Deal Talks With Boston Scientific -- Update

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/13/2018 | 04:11pm CEST

By Aisha Al-Muslim

Medical-technology company Stryker Corp. said Wednesday it is not in discussions with Boston Scientific Corp. regarding a potential takeover.

On Monday, The Wall Street Journal reported Stryker had made a takeover approach to Boston Scientific, a move that would create a medical-device giant and would be the latest effort to consolidate a corner of the health-care industry that has produced a raft of large deals lately.

Stryker said in a filing with the Securities and Exchange Commission on Wednesday it doesn't typically comment on these matters, but it chose to respond following market speculation about a possible deal for Boston Scientific.

Stryker's filing didn't dispute that it had made a takeover approach.

The Journal had reported it wasn't clear how receptive Boston Scientific was to a deal. Boston Scientific said in a statement after the Journal reported on the advance Monday that it was aware of the report but declined to comment.

Boston Scientific declined to comment Wednesday after Stryker's filing.

Stryker, based in Kalamazoo, Mich., is one of the largest makers of knee- and hip-replacement parts, competing with companies including Johnson & Johnson and Zimmer Biomet Holdings Inc.

Boston Scientific, based in Marlborough, Mass., is one of the largest makers of heart devices such as pacemakers and artery-opening stents, competing with Medtronic and Abbott Laboratories. It develops devices used in diagnosing and treating coronary artery disease, heart monitoring and a broad range of gastrointestinal and pulmonary conditions. The company also makes non-heart devices such as endoscopes, a type of surgical camera.

Stryker's shares rose more than 10% in premarket trading Wednesday. They had fallen sharply in the wake of the Journal report.

Boston Scientific's stock fell 2.1% in premarket trading Wednesday.

Write to Aisha Al-Muslim at [email protected]

Stocks mentioned in the article
ChangeLast1st jan.
BOSTON SCIENTIFIC CORPORATION -1.44% 31.835 Delayed Quote.32.96%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on STRYKER CORPORATION
06:31pSTRYKER : to host conference call on July 24, 2018
AQ
06/14STRYKER : Says It Isn't in Deal Talks -- WSJ
DJ
06/13STRYKER : Says It Isn't in Deal Talks With Boston Scientific -- Update
DJ
06/13STRYKER : Says It's Not in Deal Talks with Boston Scientific
DJ
06/13STRYKER CORP : Regulation FD Disclosure (form 8-K)
AQ
06/13STRYKER : Riverview Medical offers robotic knee replacement
AQ
06/12STRYKER : Approaches Rival Boston Scientific for Deal -- WSJ
DJ
06/11STRYKER : Makes Takeover Approach to Boston Scientific -- 2nd Update
DJ
06/11Stryker Sees Steepest One-Day Fall Since 2011 -- Data Talk
DJ
06/11STRYKER : Makes Takeover Approach to Boston Scientific -- Update
DJ
More news
News from SeekingAlpha
09:21aDIVIDEND SENSEI'S PORTFOLIO UPDATE 3 : 3 Reasons You Should Avoid This Dangerous.. 
06/13Madrigal Pharma up 6% on takeover chatter 
06/13PREMARKET GAINERS AS OF 9 : 05 am (06/13/2018) 
06/13Stryker up 6% premarket on no merger discussions with Boston Scientific, BSX .. 
06/11Sell-siders weigh in on possible Boston Scientific - Stryker marriage 
Financials ($)
Sales 2018 13 603 M
EBIT 2018 3 425 M
Net income 2018 2 300 M
Debt 2018 4 038 M
Yield 2018 1,08%
P/E ratio 2018 28,05
P/E ratio 2019 24,01
EV / Sales 2018 4,92x
EV / Sales 2019 4,53x
Capitalization 62 925 M
Chart STRYKER CORPORATION
Duration : Period :
Stryker Corporation Technical Analysis Chart | SYK | US8636671013 | 4-Traders
Technical analysis trends STRYKER CORPORATION
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 181 $
Spread / Average Target 6,5%
EPS Revisions
Managers
NameTitle
Kevin A. Lobo Chairman, President & Chief Executive Officer
Lonny J. Carpenter Group President-Global Quality & Operations
Glenn S. Boehnlein Chief Financial Officer & Vice President
Bijoy Sagar Chief Information Officer & Vice President
Ronda E. Stryker Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
STRYKER CORPORATION8.74%62 925
SMITH & NEPHEW6.17%15 885
WRIGHT MEDICAL GROUP NV16.31%2 736
JAPAN LIFELINE CO., LTD.12.98%2 197
GLAUKOS CORP67.72%1 502
CERUS CORPORATION107.10%884